Permanent chemotherapy-induced alopecia presenting with erosive pustular dermatosis-like retention hyperkeratosis

Avani Kolla, BPhil, Lynn Liu, BS, Jeremy Freedman, MD, Nkemjika Ugonabo, MD, Genevieve Kaunitz, MD, Emily Milam, MD, Kristen Lo Sicco, MD, and Nooshin K. Brinster, MD
New York, New York

Key words: chemotherapy-induced alopecia; hair loss; retention hyperkeratosis; trichoscopy.

INTRODUCTION
Reports of permanent chemotherapy-induced alopecia (pCIA), defined as the absence or incomplete regrowth of hair for ≥6 months following completion of chemotherapy, are increasing. Most often associated with taxane-based chemotherapies and endocrine therapies, it affects 42% of breast cancer survivors.1,2 While most patients present with diffuse hair thinning, our patient presented with brown plaques in addition to hair loss.

CASE REPORT
A 70-year-old woman with a history of stage IIIB breast cancer presented with brown scaly plaques on the scalp and hair loss, associated with mild pruritus and no history of scalp trauma. The plaques appeared after she had developed chemotherapy-induced alopecia upon completion of breast cancer treatment with paclitaxel 1 year previously. Clinical exam revealed diffuse alopecia with large, thick, adherent plates of brown scale over the vertex and frontal aspect of the scalp (Fig 1). Retention of hair and smaller plaques were present on the occipital scalp. Gentle scale removal revealed a white-to-pink pustular-like base. Fungal culture was negative, and punch biopsy from the frontal aspect of the scalp showed retention hyperkeratosis. Improvement occurred following 4 weeks of treatment with Silvadene cream daily and a 14-day course of doxycycline 100 mg twice daily. Her maintenance regimen included daily compounded 6% salicylic acid with mineral oil, fluocinolone 0.01% topical oil, and alternating between ketoconazole 2% and T-Sal shampoos.

Five months after initial biopsy, the retention hyperkeratosis resolved; however, the patient expressed concern regarding lack of hair regrowth. The hair loss extended beyond the region of preceding erosive pustular dermatosis (EPD)-like retention hyperkeratosis, and she had decreased density of eyebrow and eyelash hair. The patient had no family history of alopecia but noted thin hair at baseline with a receding hairline that preceded chemotherapy. Dermoscopy demonstrated yellow globules, decreased follicular ostia, and mild scaling. Punch biopsy of posterior parietal scalp showed late-stage nonscarring alopecia with diminished follicular density, preserved sebaceous glands, and miniaturized follicles, most consistent with pCIA; there was no fibrosis or evidence of EPD (Fig 2). The patient’s final diagnosis was EPD-like retention hyperkeratosis with pCIA. At last follow-up, the patient had been on minoxidil 5% foam twice daily for 8 months as well as spironolactone 50 mg twice daily for 5 months.

Abbreviations used:
pCIA: permanent chemotherapy-induced alopecia
EPD: erosive pustular dermatosis

From the Ronald O. Perelman Department of Dermatology, NYU Grossman School of Medicine.
Authors Kolla and Liu contributed equally to this article.
Funding sources: None.
IRB approval status: The patient in this manuscript has given written informed consent to publication of their case details.
Correspondence to: Nooshin K. Brinster, MD, Bridge Dermatopathology, 560 White Plains Road, Tarrytown, NY 10591. E-mail: nooshin.brinster@bridgedermpath.com.

JAAD Case Reports 2022;21:77-9.
2352-5126
© 2022 by the American Academy of Dermatology, Inc. Published by Elsevier, Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
https://doi.org/10.1016/j.jdcr.2021.12.025
DISCUSSION

Clinical features of pCIA typically include non-scarring alopecia with diffuse hair thinning, often with a pattern similar to androgenetic alopecia, and eyelash, eyebrow, axillary, and pubic hair loss. Histopathologic findings of pCIA include reduction in hair density, miniaturization, and end-stage fibrous tracts. To our knowledge, thick plate-like scaling with an erosive scalp has not been reported previously as an associated clinical finding of pCIA. The etiology of EPD and retention hyperkeratosis are not fully known and may be triggered by trauma. Chemotherapy could trigger EPD or retention hyperkeratosis, but this does not explain the patient’s single episode, which usually follows a chronic recurrent course.

pCIA can be distressing, with negative impact on quality of life and self-esteem. Prevention with scalp cooling, prompt diagnosis, and early treatment may help reduce morbidity. There are currently no guidelines for the treatment of pCIA, in part due to its incompletely understood pathogenesis. One hypothesis is that chemotherapies unmask underlying androgenetic alopecia in women, so this patient was treated with spironolactone, an androgen receptor antagonist. The patient was also treated with topical minoxidil 5%, a common treatment for CIA that has shown mixed results for pCIA. Oral minoxidil and platelet rich plasma may be considered as future treatments.

In conclusion, rare presentations of pCIA may include thick plate-like scaling resembling EPD. Repeat biopsy after clearance of lesions may allow for prompt diagnosis, and treatment for pCIA requires further research.

Conflicts of interest

None disclosed.

REFERENCES

1. Slaught C, Roman M, Yashar S, Holland V, Goh C. Permanent alopecia in breast cancer patients: role of taxanes and endocrine therapies. Cutis. 2021;107(3):E17-E22. https://doi.org/10.12788/cutis.0215
2. Kang D, Kim IR, Choi EK, et al. Permanent chemotherapy-induced alopecia in patients with breast cancer: a 3-year prospective cohort study. Oncologist. 2019;24(3):414-420. https://doi.org/10.1634/theoncologist.2018-0184
3. Rossi A, Fortuna MC, Caro G, et al. Chemotherapy-induced alopecia management: clinical experience and practical advice. J Cosmet Dermatol. 2017;16(4):537-541. https://doi.org/10.1111/jocd.12308
4. Freites-Martínez A, Shapiro J, van den Hurk C, et al. Hair disorders in cancer survivors. J Am Acad Dermatol. 2019;80(5):1199-1213. https://doi.org/10.1016/j.jaad.2018.03.056
5. Tallon B, Blanchard E, Goldberg LJ. Permanent chemotherapy-induced alopecia: histopathologic criteria still to be defined. J Am Acad Dermatol. 2013;68(5):e151-e152. https://doi.org/10.1016/j.jaad.2010.07.019
6. Fonia A, Cota C, Setterfield JF, Goldberg LJ, Fenton DA, Stefanato CM. Permanent alopecia in patients with breast...
cancer after taxane chemotherapy and adjuvant hormonal therapy: clinicopathologic findings in a cohort of 10 patients. J Am Acad Dermatol. 2017;76(5):948-957. https://doi.org/10.1016/j.jaad.2016.12.027

7. Chon SY, Champion RW, Geddes ER, Rashid RM. Chemotherapy-induced alopecia. J Am Acad Dermatol. 2012;67(1):e37-e47. https://doi.org/10.1016/j.jaad.2011.02.026

8. Lemieux J, Maunsell E, Provencher L. Chemotherapy-induced alopecia and effects on quality of life among women with breast cancer: a literature review. Psychooncology. 2008;17(4):317-328. https://doi.org/10.1002/pon.1245

9. Ross M, Fischer-Cartlidge E. Scalp cooling: a literature review of efficacy, safety, and tolerability for chemotherapy-induced alopecia. Clin J Oncol Nurs. 2017;21(2):226-233. https://doi.org/10.1188/17.CJON.226-233

10. Rubio-Gonzalez B, Juhasz M, Fortman J, Mesinkovska NA. Pathogenesis and treatment options for chemotherapy-induced alopecia: a systematic review. Int J Dermatol. 2018;57(12):1417-1424. https://doi.org/10.1111/ijd.13906

11. Yang X, Thai KE. Treatment of permanent chemotherapy-induced alopecia with low dose oral minoxidil. Australas J Dermatol. 2016;57(4):e130-e132. https://doi.org/10.1111/ajd.12950